Insulin-like growth factor-I decreases serum lipoprotein(a) during long- term treatment of patients with Laron syndrome

Metabolism: Clinical and Experimental

Volumn 45, Issue 10, 1996, Pages 1263-1266

  Laron, Z ^a   Wang, X L ^b   Klinger, B ^b   Silbergeld, A ^b   Wilcken, D E L ^b  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FK 780; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROGENESIS; CHILD; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; LARON SYNDROME; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029795156     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90245-0     Document Type: Article

References (36)

1. Scanu AM, Fless GM: Lipoprotein(a): Structural considerations with an emphasis on heterogeneity, in Beam AG (ed): Genetics of Coronary Heart Disease. Olso, Norway, Institute of Medical Genetics, University of Oslo, 1992, pp 23-32
2. Utermann G: The mysteries of lipoprotein(a). Science 246:904-910, 1989
3. Scanu AM, Fless GM: Lipoprotein(a). Heterogeneity and biological relevance. J Clin Invest 85:1709-1715, 1990
4. Lackner C, Boerwinkle E, Leffert CC, et al: Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87:2077-2086, 1991
5. Cohen JC, Chiesa G, Hobbs HH: Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 91:1630-1636, 1993
6. Boerwinkle E, Fornage M: Genetics of Lp(a) lipoprotein. An evolving paradigm, in Beam AG (ed): Genetics of Coronary Heart Disease. Olso, Norway, Institute of Medical Genetics, University of Oslo, 1992, pp 33-52
7. Trommsdorff M, Kochl S, Lingenhel A, et al: A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest 96:150-157, 1995
8. Wang XL, Wilcken DEL, Dudman NPB: Early expression of apolipoprotein(a) gene: Relationships between infants' and their parents' serum apolipoprotein(a) levels. Pediatrics 89:401-406, 1992
9. Wilcken DEL, Wang XL, Greenwood J, et al: Lipoprotein(a), apolipoprotein B and AI in children and coronary events in their grandparents. J Pediatr 123:519-526, 1993
10. Black IW, Wilcken DEL: Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 38:353-357, 1992
11. Parra HJ, Mezdour H, Cachera C, et al: Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 33:721-722, 1987
12. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipaemic subjects treated with nicotinic acid. J Intern Med 226:271-276, 1989
13. Kuusi T, Yki-Jarvinen H, Kauppinen-Makelin R, et al: Effect of insulin treatment on serum lipoprotein(a) in non-insulin-dependent diabetes. Eur J Clin Invest 25:194-200, 1995
14. Dullaart RP, van Doormaal JJ, Hoogenberg K, et al: Triiodothyronine rapidly lowers plasma lipoprotein(a) in hypothyroid subjects. Neth J Med 46:179-184, 1995
15. Sacks FM, McPherson R, Walsh BW: Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 154:1106-1110, 1994
16. Soma MR, Osnago-Gadda I, Paoletti R, et al: The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 153: 1462-1468, 1993
17. Laron Z, Klinger B, Jensen LT, et al: Biochemical and hormonal changes induced by one week of administration of IGF-I to patients with Laron type dwarfism. Clin Endocrinol 35:145-150, 1991
18. Laron Z, Klinger B: IGF-I treatment of adult patients with Laron syndrome: Preliminary results. Clin Endocrinol (Oxf) 41:631-638, 1994
19. Larson Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism? Isr J Med Sci 2:152-155, 1966
20. Laron Z: Laron syndrome - From description to therapy. Endocrinologist 3:21-28, 1993
21. Laron Z, Blum W, Chatelain P, et al: Classification of growth hormone insensitivity syndrome. J Pediatr 122:241, 1993
22. Wang XL, Wilcken DEL, Dudman NPB: An indirect sandwich ELISA for Lp(a) in serum and dried blood spots. Clin Chim Acta 207:73-86, 1992
23. Larson Z, Pertzelan A, Karp M, et al: Laron syndrome - A unique model of IGF-I deficiency. Pediatr Adolesc Endocrinol 24:3-23, 1993
24. Larson Z, Pertzelan A, Karp M: Pituitary dwarfism with high serum levels of growth hormone. Isr J Med Sci 4:883-894, 1968
25. Laron Z: Laron-type dwarfism (hereditary somatomedin deficiency): A review, in Advances in Internal Medicine and Pediatrics. van Frick P, von Harnack GA, Kochsiek K, et al: (eds): Berlin, Germany, Springer Verlag, 1984, pp 117-150
26. Laron Z, Pertzelan A, Karp M, et al: Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor metabolic and linear growth responses. J Clin Endocrinol Metab 33:332-342, 1971
27. Eshet R, Laron Z, Pertzelan A, et al: Defect of human growth hormone receptors in the liver of two patients with Larson type dwarfism. Isr J Med Sci 20:8-11, 1984
28. Godowski PJ, Leung DW, Meacham LR, et al: Characterization of the human growth hormone receptor gene and the demonstration of partial gene deletion in Laron-type dwarfism. Proc Natl Acad Sci USA 86:8083-8087, 1989
29. Amselem S, Duquesnoy P, Duriez B, et al: Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. 4:355-359, 1993
30. Laron Z, Klinger B, Eshet R, et al: Laron syndrome due to a post-receptor defect: Response to IGF-I treatment. Isr J Med Sci 29:757-763, 1993
31. Klinger B, Laron Z: Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr Nephrol 8:684-688, 1994
32. Laron Z, Klinger B: Body fat in Laron syndrome patients: Effect of insulin-like growth factor treatment. Horm Res 40:16-22, 1993
33. Laron Z, Avitzur Y, Klinger B: Carbohydrate metabolism in primary GH resistance (Laron syndrome) before and during IGF-I treatment. Metabolism 44:113-118, 1995 (suppl 4)
34. Labeur C, Rosseneu M, Henderson O: International Lp(a) standardization. Chem Phys Lipids 67:265-270, 1994
35. Sgoutas DS, Tuten T: Effect of lyophilization on determinations of lipoprotein(a) in serum. Clin Chem 38:1355-1360, 1992
36. Helmhold M, Bigge J, Muche R, et al: Contribution of the apo(a) phenotype to plasma Lp(a) concentrations show considerable ethnic variation. J Lipid Res 32:1919-1928, 1991